AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 27217446
Drug: Bevacizumab (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bevacizumab (15 mg/kg) plus Fosbretabulin (60 mg/m(2) intravenously once every 3 weeks)
Trial: 22902784
Drug: Self-administered intradermal
RxNorm normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Self-administered intradermal influenza vaccine
Trial: 22902784
Drug: Nurse-administered intradermal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-administered intradermal influenza vaccine
Trial: 24290423
Drug: Interventional fetal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interventional fetal medicine randomised controlled trial (RCT)
Trial: 20213469
Drug: Maximal agonist
RxNorm normalized name: Spirulina maxima preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal agonist torque estimated from resultant and antagonist torques in plantar-flexion (PF) and dorsi-flexion (DF).
Trial: 10831026
Drug: Fluvoxamine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine treatment (100-300 mg/day) for 10 weeks
Trial: 8624271
Drug: Response to
RxNorm normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Response to 6 months of first-line chemotherapy
Trial: 30610155
Drug: Omeprazole (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (20 mg twice daily for 3 months)
Trial: 26866364
Drug: Carvedilol 6.25
RxNorm normalized name: carvedilol 6.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol 6.25 mg daily during chemotherapy
Trial: 24961324
Drug: Actovegin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actovegin (250 ml, 4 mg/ml) as monotherapy for 10 days
Trial: 24961324
Drug: Dextranes and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextranes and pentoxyphyllin (100 mg/day)
Trial: 20040339
Drug: Alogliptin 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 100 mg under fed conditions
Trial: 20040339
Drug: Alogliptin 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 100 mg under fasted conditions
Trial: 20040339
Drug: Alogliptin 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 100 mg q.d. + Metformin 1,000 mg b.i.d.
Trial: 20040339
Drug: Alogliptin 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 100 mg q.d. + Cimetidine 400 mg q.d.
Trial: 20040339
Drug: Alogliptin 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 100 mg q.d. alone
Trial: 20040339
Drug: Alogliptin 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alogliptin 100 mg q.d. + Metformin 1,000 mg b.i.d. and Alogliptin 100 mg q.d. + Cimetidine 400 mg q.d.
Trial: 17622869
Drug: Intermittent feeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent feeding regimen (one‐sixth of daily needs infused every 4 hours)
Trial: 10548325
Drug: Arizona Food
RxNorm normalized name: Arizona ash pollen extract
DrugBank: Fraxinus velutina pollen (DB10455)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arizona Food Frequency Questionnaire (AFFQ) administered at baseline and year 1
Trial: 7751430
Drug: Bisoprolol 5
RxNorm normalized name: bisoprolol 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisoprolol 5 mg and Hydrochlorothiazide 6.25 mg (B5/H6.25)
Trial: 7751430
Drug: Hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg (H25)
Trial: 2340838
Drug: Sinemet-controlled release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinemet-controlled release (CR4) 50 mg carbidopa/200 mg levodopa
Trial: 30565745
Drug: Probiotics and
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics and lactoferrin (2 capsules/day for 5 days followed by 1 capsule/day for additional 10 days, then 1 capsule/day for 10 consecutive days each month for 6 months)
Trial: 30565745
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 capsules/day for 5 days followed by 1 capsule/day for additional 10 days, then 1 capsule/day for 10 consecutive days each month for 6 months)
Trial: 16953529
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg intravenous morphine
Trial: 15364136
Drug: Concurrent chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent chemoradiotherapy (CRT) with cisplatin and vinorelbine; cisplatin 80 mg/m² on day 1, vinorelbine 25 mg/m² on days 1 and 4 of cycles 1 and 4, and 12.5 mg/m² during cycles 2 and 3; RT started on day 4 of cycle 2.
Trial: 15364136
Drug: Sequential chemoradiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential chemoradiotherapy (CRT) with cisplatin and vinorelbine; same chemotherapy regimen as concurrent arm; RT started within 2 weeks after completion of chemotherapy.
Trial: 15364136
Drug: Concurrent CRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent CRT
Trial: 15364136
Drug: Sequential CRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential CRT
Trial: 10714910
Drug: Micronised 17beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronised 17beta oestradiol (2 mg daily) + dydrogesterone (5-20 mg for last 14 days)
Trial: 1731540
Drug: 1000 mL
RxNorm normalized name: TPN Bag 1000 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mL of 5% dextrose + 1000 mL of Ringers solution (RS) + 250 mL of 5% human albumin (HA)
Trial: 1731540
Drug: 1750 mL
RxNorm normalized name: ALCOHOL 1465.1 mL in 1750 mL TOPICAL LIQUID [Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1750 mL of RS + 500 mL of 3.5% gelatin
Trial: 1731540
Drug: 1850 mL
RxNorm normalized name: CATHETER,URETHRAL 16FR 5CC F#762-1850
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1850 mL of RS + 400 mL of 20% HA
Trial: 1731540
Drug: 1750 mL
RxNorm normalized name: ALCOHOL 1465.1 mL in 1750 mL TOPICAL LIQUID [Hand Sanitizer]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1750 mL of RS + 500 mL of 10% low molecular weight hydroxyethyl starch
Trial: 1731540
Drug: 2250 mL
RxNorm normalized name: ALCOHOL 2250 mL in 3000 mL TOPICAL LIQUID [EXIHUAN Disinfectant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2250 mL of RS
Trial: 31747825
Drug: OnabotulinumtoxinA injections
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: OnabotulinumtoxinA injections combined with upper-limb physiotherapy
Trial: 31747825
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections combined with upper-limb physiotherapy
Trial: 22465175
Drug: Potassium-sparing diuretics
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium-sparing diuretics (N = 192)
Trial: 19307987
Drug: Medication and
RxNorm normalized name: CVS Health Medication and Topical Refill Pouch KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication and behavioral treatment
Trial: 19307987
Drug: Parent report
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parent report of medication adherence
Trial: 17710011
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose remifentanil (0.4 microg/kg/min)
Trial: 17710011
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose remifentanil (0.1 microg/kg/min)
Trial: 11558855
Drug: GP IIb/IIIa-receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GP IIb/IIIa-receptor inhibitors
Trial: 9678793
Drug: Stem cell
RxNorm normalized name: Stem cells, apheresis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stem cell factor (SCF) 20 microg/kg plus G‐CSF
Trial: 9678793
Drug: SCF 20
RxNorm normalized name: Immunoglobulin scfv-scfv-scfc, anti-(homo sapiens dll3 (delta-like ligand 3)) and anti-(homo sapiens cd3e (cd3 epsilon, leu-4)), monoclonal antibody single chain (scfv)2-scfc, bispecific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCF 20 microg/kg plus G‐CSF 5 microg/kg
Trial: 9678793
Drug: SCF administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SCF administration
Trial: 8205878
Drug: IPV with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPV with 2.5 mg albuterol (internal percussive component activated)
Trial: 8205878
Drug: IPV with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IPV with 2.5 mg albuterol (internal percussive component inactivated) followed by P&PD
Trial: 8205878
Drug: Nebulizer with
RxNorm normalized name: AeroNeb Go Nebulizer with Cable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulizer with 2.5 mg albuterol followed by P&PD
Trial: 2913847
Drug: Prophylactic transdermal
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic transdermal scopolamine patches
Trial: 22302453
Drug: Comprehensive periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comprehensive periodontal treatment during pregnancy
Trial: 22302453
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (one session of supragingival scaling and oral hygiene instruction after delivery)
Trial: 21777233
Drug: Albendazole plus
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole plus antiepileptics
Trial: 21777233
Drug: Antiepileptics only
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptics only
Trial: 15651177
Drug: Lipid formulation
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipid formulation of amphotericin B or echinocandin
Trial: 31013539
Drug: Early Premature
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early Premature Infant Oral Motor Intervention (PIOMI), given 15 to 30 minutes before feeding once a day for 14 days
Trial: 31013539
Drug: Early Premature
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early Premature Infant Oral Motor Intervention (PIOMI)
Trial: 28712955
Drug: ΔRVSWI ≤1.07
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ΔRVSWI ≤1.07 mm Hg⋅L⋅m-2 and ΔLVSWI ≤4.57 mm Hg⋅L⋅m-2
Trial: 25528363
Drug: FGF-23 levels
RxNorm normalized name: peanut allergenic extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FGF-23 levels above the median (395 RU/mL)
Trial: 15836716
Drug: RBC 400
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC 400 mg b.d., amoxicillin 1 g b.d., and clarithromycin 500 mg b.d. (RAC group, n = 28)
Trial: 15836716
Drug: RBC 400
RxNorm normalized name: Ultratag RBC KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RBC 400 mg b.d., metronidazole 500 mg b.d., and tetracycline 500 mg b.d. (RMT group, n = 28)
Trial: 15836716
Drug: First-line Maastricht
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line Maastricht therapy
Trial: 10986030
Drug: Topical autologous
RxNorm normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical autologous platelet lysate applied twice per week for up to 9 months in combination with standardised compression bandaging
Trial: 10986030
Drug: Placebo buffer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo buffer solution applied twice per week for up to 9 months in combination with standardised compression bandaging
Trial: 1944755
Drug: Ciclosporin and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclosporin and low-dose prednisone
Trial: 6864445
Drug: Experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental group (exposed to two treatments designed to reduce imitation of aggressive behaviors)
Trial: 6864445
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (received comparable neutral treatments)
Trial: 31419080
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic Acid (TXA) 1 g
Trial: 19318634
Drug: Factor D
RxNorm normalized name: Factor D
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Factor D (50 microg selenium, 30 mg vitamin E, and 15 mg beta-carotene)
Trial: 11995457
Drug: IL-2 preoperative
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-2 preoperative immunotherapy (12 million IU/day subcutaneously for 3 consecutive days prior to surgery)
Trial: 11995457
Drug: IL-2 preoperative
RxNorm normalized name: Ile
DrugBank: Isoleucine (DB00167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IL-2 preoperative immunotherapy
Trial: 10431942
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg of caffeine (placebo)
Trial: 30777122
Drug: Consult for
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Consult for Addiction Treatment and Care in Hospitals (CATCH) model
Trial: 25343955
Drug: Aryoseven (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aryoseven (90 to 120 μg/kg intravenously every 2 hours)
Trial: 25343955
Drug: Novoseven (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novoseven (90 to 120 μg/kg intravenously every 2 hours)
Trial: 20112413
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy (laser therapy, steroid injections) for partial and nonresponders
Trial: 12435698
Drug: Intravenous ARS
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ARS (2.4 mg/kg) followed by intramuscular ARS (1.2 mg/kg)
Trial: 12435698
Drug: Intramuscular ARS
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ARS (2.4 mg/kg) followed by intravenous ARS (1.2 mg/kg)
Trial: 12435698
Drug: Intramuscular ARS
RxNorm normalized name: AR-9281
DrugBank: AR-9281 (DB06345)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular ARS
Trial: 1955508
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human GH (hGH) 3 IU (1.25 mg)/m2.day, administered via sc injections 6 days/week, either in the morning or in the evening for 12 months
Trial: 1955508
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human GH (hGH) 3 IU (1.25 mg)/m2.day, administered via sc injections 6 days/week
Trial: 6791491
Drug: Parenteral nutrition
RxNorm normalized name: parenteral nutrition solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral nutrition regimen adequate in amino acids and glucose
Trial: 30728043
Drug: Practice-specific antibiotic-prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Practice-specific antibiotic-prescription feedback and educational outreach visit, including e-learning modules and tablet PCs with information on antibiotics.
Trial: 30728043
Drug: Narrow-spectrum antibiotics.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrow-spectrum antibiotics.
Trial: 30728043
Drug: Broad-spectrum antibiotics.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Broad-spectrum antibiotics.
Trial: 27342514
Drug: No hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No hydroxyurea therapy
Trial: 25189626
Drug: Invasive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive treatment (coronary angiography and intervention if feasible)
Trial: 19149822
Drug: 7-day taper
RxNorm normalized name: ZCORT 7-Day Tapered 1.5mg Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day taper
Trial: 19149822
Drug: 28-day taper
RxNorm normalized name: CAPER BERRY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28-day taper
Trial: 389825
Drug: Bacampicillin 800
RxNorm normalized name: bacampicillin 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bacampicillin 800 mg t.i.d. for ten days
Trial: 389825
Drug: Ampicillin 2
RxNorm normalized name: ampicillin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin 2 g t.i.d. for ten days
Trial: 31305347
Drug: Titanium curette
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Titanium curette treatment
Trial: 31305347
Drug: Carbon fiber
RxNorm normalized name: fiber
DrugBank: Calcium polycarbophil (DB14684)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbon fiber reinforced plastic curette treatment
Trial: 31305347
Drug: Ultrasonic scaling
RxNorm normalized name: wing scale pollen extract
DrugBank: Atriplex canescens pollen (DB10767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonic scaling with carbon fiber tip treatment
Trial: 18647614
Drug: Morphosemantic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphosemantic treatment
Trial: 18647614
Drug: Morphophonological treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphophonological treatment
Trial: 12974569
Drug: Concurrent reproduction
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent reproduction
Trial: 12974569
Drug: Both concurrent
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both concurrent and delayed conditions
Trial: 1329698
Drug: High-dose cyclosporine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclosporine
Trial: 1329698
Drug: Corticosteroids and
RxNorm normalized name: Corticosteroids and mydriatics in combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids and cyclosporine (combination therapy)
Trial: 6149592
Drug: Dopamine agonist,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine agonist, apomorphine (AP)
Trial: 6149592
Drug: Dopamine receptor
RxNorm normalized name: Dopamine receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine receptor blockade
Trial: 31075323
Drug: Mediterranean/low-carbohydrate diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean/low-carbohydrate diet (MED/LC + 28 g walnuts/day)
Trial: 27045811
Drug: Daily boost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily boost of 0.5 Gy
Trial: 27045811
Drug: Weekly boost
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Weekly boost of 2 Gy
Trial: 26090731
Drug: Standard radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard radiation dose
Trial: 26090731
Drug: 37% reduced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 37% reduced radiation dose
Trial: 9190510
Drug: Rehabilitation plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rehabilitation plus relaxation therapy (six weekly sessions of breathing and relaxation instruction)
Trial: 8109770
Drug: Ketorolac infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac infusion (30 mg IM premedication + 2 mg/h continuous infusion)
Trial: 8109770
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (NaCl 0.9% IM bolus + 2 mL/h saline infusion)
Trial: 2470245
Drug: FUra +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUra + LV* (high dose 200 mg/m2)
Trial: 2470245
Drug: FUra +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUra + LV* (low dose 20 mg/m2)
Trial: 2470245
Drug: FUra (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUra (single agent)
Trial: 2470245
Drug: FUra +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUra + LV* (both doses)
Trial: 30302936
Drug: AZL‐M/CLD 40/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZL‐M/CLD 40/25 mg
Trial: 30302936
Drug: AZL‐M/CLD 40/12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZL‐M/CLD 40/12.5 mg
Trial: 30302936
Drug: AZL‐M 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZL‐M 40 mg
Trial: 24576271
Drug: Multidisciplinary group-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary group-based rehabilitation program with monthly motivational consultation from 6 to 12 months
Trial: 20923610
Drug: AS03(B) adjuvanted
RxNorm normalized name: hepatitis B surface antigen vaccine
DrugBank: Hepatitis B Vaccine (Recombinant) (DB11627)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03(B) adjuvanted split-virion H1N1 vaccine
Trial: 20923610
Drug: Non-adjuvanted whole-virion
RxNorm normalized name: HYACINTHOIDES NON-SCRIPTA WHOLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted whole-virion H1N1 vaccine
Trial: 8245328
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy (recombinant tissue-type plasminogen activator, urokinase, or a combination)
Trial: 3802956
Drug: Low-dose recombinant
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose recombinant interferon-alpha-2a (1.5 X 10(6) U daily for one week)